RESUMEN
Tenofovir disoproxil fumarate (TDF) is still widely prescribed for human immunodeficiency virus (HIV)-infected pregnant women, despite its renal and bone toxicity. Although TDF-exposed infants often show transient growth impairment, it is not clear whether maternal TDF causes infantile rickets via maternal/fetal renal dysfunction in Asian populations. This prospective observational study was conducted in Vietnam and involved pregnant HIV-infected women treated with TDF-based regimen (TDF group) or zidovudine-based regimen (AZT-group). At birth, 3, 12, and 18 months of age, and included body length, weight, head circumference, serum alkaline phosphatase (ALP), creatinine, calcium, phosphorus, urine-ß2-microglobulin (U-BMG), percentage of tubular reabsorption of phosphate (%TRP), and radiographic wrist score for rickets. Age-adjusted multivariate linear regression analysis evaluated the association of TDF/AZT use during pregnancy with fetal renal function and bone health. The study included 63 mother-infant pairs (TDF group = 53, AZT group = 10). In the mothers, detectable U-BMG (>252 µg/L) was observed more frequently in the TDF- than AZT group (89 vs 50%, p<0.001), but other renal/bone parameters were similar. In infants, maternal TDF use was not associated with growth impairment, renal dysfunction, or abnormal bone findings, but with a slightly higher ALP levels (p = 0.019). However, shorter length was associated with maternal AZT (p = 0.021), and worse radiographic scores were associated with LPV/r (p = 0.024). In Vietnamese population, TDF usage during pregnancy was not associated with infant transient rickets, growth impairment, or renal dysfunction, despite mild maternal tubular impairment. Maternal AZT and LPV/r influenced infant growth and bone health, though further studies are needed to confirm this finding.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Exposición Materna/efectos adversos , Tenofovir/efectos adversos , Zidovudina/efectos adversos , Microglobulina beta-2/orina , Estatura/efectos de los fármacos , Endopeptidasas/sangre , Femenino , Humanos , Lactante , Masculino , Análisis Multivariante , Embarazo , Mujeres Embarazadas , Estudios Prospectivos , Tenofovir/uso terapéutico , Vietnam , Zidovudina/uso terapéuticoAsunto(s)
Lupus Eritematoso Sistémico/diagnóstico , Úlceras Bucales/complicaciones , Adolescente , Anticuerpos Antinucleares/sangre , Endopeptidasas/sangre , Fiebre/etiología , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/tratamiento farmacológico , Masculino , Úlceras Bucales/tratamiento farmacológico , Esteroides/uso terapéutico , Resultado del TratamientoAsunto(s)
Endotoxinas/inmunología , Infecciones por Escherichia coli/inmunología , Escherichia coli/fisiología , Granulocitos/fisiología , Complejo de Antígeno L1 de Leucocito/sangre , Neutrófilos/fisiología , Sepsis/inmunología , Células Cultivadas , Endopeptidasas/sangre , Voluntarios Sanos , Receptor Celular 1 del Virus de la Hepatitis A/sangre , Humanos , Interleucina-6/sangre , Lipocalina 2/sangre , Sepsis/diagnóstico , Regulación hacia ArribaRESUMEN
PURPOSE: The aim of this study is to investigate which ADAMTS genes play a major role in the development of primary hip osteoarthritis, by comparing the tissue and blood samples in patients with hip osteoarthritis and a control group. MATERIAL AND METHODS: Human articular cartilage was obtained from femoral heads of 15 patients with end stage osteoarthritis undergoing total hip replacement. As the control group, the cartilages was obtained from femoral heads of 15 patients, who did not have osteoarthritis or degenerative changes in hip joint, undergoing hip replacement following the fracture of the femoral neck. After the cartilage samples were taken from the resection materials, the DNA polymorphisms in the patients' cartilage samples were tested by Polymerase Chain Reaction (PCR), the serum levels of aggrecanase genes were analyzed with Enzyme-Linked ImmunoSorbent Assay (ELISA). RESULTS: The level of ADAMTS5 and ADAMTS9 genes were found significantly lower as a result of ELISA analysis degenerative arthritis group than the control group (p < 0,05). ADAMTS 1, 4, 8, 15 were similar between the two groups in ELISA analysis (p > 0,05). As a result of quantitative real time RT-PCR analysis, the level of ADAMTS8 mRNA increased 3.5 fold in hip degenerative arthritis group when compared with femoral neck fractures group. ADAMTS1, ADAMTS4 and ADAMTS5 expression levels in hip degenerative arthritis group were decreased 2.5, 2 and 2.5 fold, respectively. ADAMTS9, 15 were found to be similar between two groups. CONCLUSON: As a result of this study on hip osteoarthritis, the ADAMTS8 levels was found to be significantly higher in the end stage of hip osteoarthritis. Unlike similar studies on knee osteoarthritis, ADAMTS1,4,5 levels were found to be lower.
Asunto(s)
Proteínas ADAMTS/genética , Proteína ADAMTS1/genética , Cartílago Articular , Endopeptidasas , Osteoartritis de la Cadera , Proteínas ADAMTS/análisis , Anciano , Artroplastia de Reemplazo de Cadera/métodos , Cartílago Articular/enzimología , Cartílago Articular/patología , Correlación de Datos , Endopeptidasas/sangre , Endopeptidasas/genética , Femenino , Fracturas del Cuello Femoral/genética , Fracturas del Cuello Femoral/patología , Fracturas del Cuello Femoral/cirugía , Perfilación de la Expresión Génica/métodos , Humanos , Masculino , Persona de Mediana Edad , Osteoartritis de la Cadera/sangre , Osteoartritis de la Cadera/genética , Osteoartritis de la Cadera/patología , Osteoartritis de la Cadera/cirugíaRESUMEN
BACKGROUND: Lumbrokinase (LK) is an enzyme complex with antithrombotic, antioxidant, antitumor, and immunomodulatory effects. It has been extensively studied and used in clinical anti-tumor therapy. However, its half-life is short, its bioavailability is low, and its toxicity and side effects are great, which greatly limit its clinical application. Therefore, LK is often combined with other drugs (such as immune agents, hormones, or Chinese herbal medicine) to reduce its dosage and side effects and to improve its anti-tumor effects. METHODS AND RESULTS: Here, we described an LK/paclitaxel (PTX) nanocarrier based on poly(ethylene glycol)-b-(poly(ethylenediamine l-glutamate)-g-poly(ε-benzyoxycarbonyl-l-lysine)-r-poly(l-lysine)) (PEG-b-(PELG-g-(PZLL-r-PLL))). In the present study, LK and PTX were loaded by electrostatic and/or hydrophobic effects under mild conditions, thereby increasing the half-life and bioavailability of the drugs via the sustained release and enhancement of tumor site enrichment by the LK/PTX/PEG-b-(PELG-g-(PZLL-r-PLL)) complex through passive targeting. In this study, using bladder cancer cells (J82 cells) and rat bladder cancer model as the object, the structure of the nanocarrier, the relationship between drugs composition and antitumor properties were systematically studied. CONCLUSION: We propose that the block copolymer PEG-b-(PELG-g-(PZLL-r-PLL)) may function as a potent nanocarrier for augmenting anti-bladder cancer pharmacotherapy, with unprecedented clinical benefits.
Asunto(s)
Albúminas/uso terapéutico , Endopeptidasas/uso terapéutico , Paclitaxel/uso terapéutico , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Albúminas/farmacología , Animales , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Ciclina B1/metabolismo , Portadores de Fármacos/química , Endopeptidasas/sangre , Endopeptidasas/farmacología , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Lisina/análogos & derivados , Lisina/síntesis química , Lisina/química , Masculino , Microvasos/patología , Peso Molecular , Paclitaxel/sangre , Paclitaxel/farmacología , Polietilenglicoles/síntesis química , Polietilenglicoles/química , Polilisina/análogos & derivados , Polilisina/síntesis química , Polilisina/química , Ratas Sprague-Dawley , Carga Tumoral/efectos de los fármacos , Proteína p53 Supresora de Tumor/metabolismo , Neoplasias de la Vejiga Urinaria/sangre , Neoplasias de la Vejiga Urinaria/irrigación sanguínea , Neoplasias de la Vejiga Urinaria/patologíaRESUMEN
Protein activities and mechanisms related to aging has become a growing interest nowadays. Since SUMOylation is implicated in several cellular processes, its investigation related to senescence, aging and frailty is of high interest. In our study, wild type mice cortical lysates, synaptosomes and plasma have been processed to evaluate SUMOylation and SUMO machinery expression (Ubc9 and SENP1 enzymes) profile at different ages. In cortical lysates, SUMO-1ylation reached a peak at 6 months followed by a decrease; while in synaptosomes, it progressively increased till 18 months. Regarding SUMO-2/3ylation, it was observed a similar trend in both lysate and synaptosomes where the protein conjugation was the highest at 6 months but interestingly decreased afterwards. In addition, Ubc9 and SENP1 enzymes showed a linear increased expression level in both brain preparations. Since SUMOylation process is ubiquitously expressed, we were interested to identify SUMO conjugation at peripheral level too. Thus, SUMO-1ylation and SUMO-2/3ylation expression level has been detected in mouse plasma that revealed an inverted U-shaped curve trend during mice lifespan. Surprisingly, SENP1 enzyme was not present in the plasma while Ubc9 enzyme reached a plateau at 6 months and was highly expressed till 18 months. In conclusion, our data indicates that SUMOylation is highly correlated with age-related processes which indisputably need to be considered for further investigation.
Asunto(s)
Envejecimiento/metabolismo , Corteza Cerebral/metabolismo , Endopeptidasas/metabolismo , Proteínas Modificadoras Pequeñas Relacionadas con Ubiquitina/metabolismo , Sumoilación/fisiología , Sinaptosomas/metabolismo , Enzimas Ubiquitina-Conjugadoras/metabolismo , Envejecimiento/sangre , Animales , Cisteína Endopeptidasas , Endopeptidasas/sangre , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Proteínas Modificadoras Pequeñas Relacionadas con Ubiquitina/sangre , Enzimas Ubiquitina-Conjugadoras/sangreRESUMEN
Direct oral anticoagulants (DOACs) can be quantified using methods that can be performed in any clinical or research laboratory using manual or automated instrument platforms. Dabigatran etexilate, the oral direct thrombin inhibitor, can be quantified by drug-calibrated clot or chromogenic-based assays using either thrombin or ecarin as substrates. Oral direct anti-Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban, can be quantified with drug-calibrated anti-Xa kits or reagents as typically used for measuring heparins (unfractionated, low molecular weight, or pentasaccharides).
Asunto(s)
Antitrombinas/sangre , Antitrombinas/uso terapéutico , Monitoreo de Drogas/métodos , Inhibidores del Factor Xa/sangre , Inhibidores del Factor Xa/uso terapéutico , Tiempo de Trombina/métodos , Administración Oral , Antitrombinas/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Dabigatrán/administración & dosificación , Dabigatrán/sangre , Dabigatrán/uso terapéutico , Endopeptidasas/administración & dosificación , Endopeptidasas/sangre , Endopeptidasas/uso terapéutico , Inhibidores del Factor Xa/administración & dosificación , Fibrinolíticos/administración & dosificación , Fibrinolíticos/sangre , Fibrinolíticos/uso terapéutico , Humanos , Pirazoles/administración & dosificación , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridinas/administración & dosificación , Piridinas/sangre , Piridinas/uso terapéutico , Piridonas/administración & dosificación , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán/administración & dosificación , Rivaroxabán/sangre , Rivaroxabán/uso terapéutico , Tiazoles/administración & dosificación , Tiazoles/sangre , Tiazoles/uso terapéutico , Tromboembolia Venosa/sangre , Tromboembolia Venosa/tratamiento farmacológicoRESUMEN
Chronic mountain sickness (CMS) results from chronic hypoxia. It is unclear why certain highlanders develop CMS. We hypothesized that modest increases in fetal hemoglobin (HbF) are associated with lower CMS severity. In this cross-sectional study, we found that HbF levels were normal (median = 0.4%) in all 153 adult Andean natives in Cerro de Pasco, Peru. Compared with healthy adults, the borderline elevated hemoglobin group frequently had symptoms (headaches, tinnitus, cyanosis, dilatation of veins) of CMS. Although the mean hemoglobin level differed between the healthy (17.1 g/dL) and CMS (22.3 g/dL) groups, mean plasma erythropoietin (EPO) levels were similar (healthy, 17.7 mIU/mL; CMS, 12.02 mIU/mL). Sanger sequencing determined that single-nucleotide polymorphisms in endothelial PAS domain 1 (EPAS1) and egl nine homolog 1 (EGLN1), associated with lower hemoglobin in Tibetans, were not identified in Andeans. Sanger sequencing of sentrin-specific protease 1 (SENP1) and acidic nuclear phosphoprotein 32 family, member D (ANP32D), in healthy and CMS individuals revealed that non-G/G genotypes were associated with higher CMS scores. No JAK2 V617F mutation was detected in CMS individuals. Thus, HbF and other classic erythropoietic parameters did not differ between healthy and CMS individuals. However, the non-G/G genotypes of SENP1 appeared to differentiate individuals with CMS from healthy Andean highlanders.
Asunto(s)
Mal de Altura/sangre , Mal de Altura/diagnóstico , Altitud , Endopeptidasas/sangre , Hemoglobina Fetal , Adaptación Fisiológica , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores , Enfermedad Crónica , Cisteína Endopeptidasas , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oxígeno/metabolismo , Perú , Fenotipo , Policitemia/sangre , Policitemia/diagnóstico , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
OBJECTIVE: To investigate the changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer. METHODS: Serum samples of patients with silicosis, tuberculosis, and lung cancer were collected. The variation trends of the expression of granzyme A, cathepsin G, apolipoprotein A, and interferon-ß (IFN-ß) were analyzed using enzyme-linked immunosorbent assay. RESULTS: The concentration of apolipoprotein A of the silicosis group was 200 µg/ml, significantly higher than those of the tuberculosis and lung cancer groups (P < 0.05), and the lung cancer group had a significantly higher concentration of apolipoprotein A compared with the tuberculosis group (P < 0.05). The silicosis group had significantly higher expression of cathepsin G compared with the tuberculosis and lung cancer groups (P < 0.05), and the tuberculosis group and lung cancer group showed no significant difference in the concentration of cathepsin G (P > 0.05). The tuberculosis group had a significantly higher concentration of granzyme A than the silicosis and lung cancer groups (P < 0.05), and the silicosis group and lung cancer group had similar protein concentration trends (P > 0.05). The tuberculosis group and lung cancer group had significantly higher concentration of IFN-ß compared with the silicosis group (P < 0.05), and the tuberculosis group and lung cancer group showed no significant difference in IFN-ß concentration (P > 0.05). CONCLUSION: This study may offer diagnostic markers for the clinical diagnosis of silicosis, tuberculosis, and lung cancer, and could provide a basis for the research, as well as potential molecular targets for the diagnosis and treatment of these diseases.
Asunto(s)
Citocinas/sangre , Endopeptidasas/sangre , Neoplasias Pulmonares/enzimología , Silicosis/enzimología , Tuberculosis/enzimología , Biomarcadores , Catepsina G/metabolismo , Ensayo de Inmunoadsorción Enzimática , Granzimas/metabolismo , Humanos , Interferón beta/metabolismoRESUMEN
Botulinum toxin was detected in patient serum using Endopeptidase-mass-spectrometry assay, although all conventional tests provided negative results. Antitoxin was administered, resulting in patient improvement. Implementing this highly sensitive and rapid assay will improve preparedness for foodborne botulism and deliberate exposure.
Asunto(s)
Botulismo/diagnóstico , Endopeptidasas/sangre , Espectrometría de Masas/métodos , Antitoxinas/administración & dosificación , Botulismo/terapia , Diagnóstico Precoz , Humanos , Lactante , Masculino , Suero/química , Factores de Tiempo , Resultado del TratamientoRESUMEN
Ghrelin is a natural GH secretagogue first identified in the stomach. The ghrelin peptide is 28 amino acids long with an octanoic acid attached to Ser(3) near the N-terminus. This lipid modification is essential for the interaction between ghrelin and the ghrelin-specific receptor GH secretagogue receptor type 1a (GHSR1a), whereas the five or more residues of the N-terminus seem to be sufficient to activate GHSR1a to the same level as those of full-length ghrelin. In this study, we found that ghrelin was converted into smaller fragments during incubation with animal plasma in vitro and in a mouse model. Mass spectrometric analysis revealed that both acyl and desacyl ghrelin were hydrolyzed at the peptide bond between Arg(15) and Lys(16), generating an N-terminal peptide consisting of the first 15 residues. Next, we partially purified a ghrelin endopeptidase from bovine plasma and identified the enzyme as an anticoagulant serine protease-activated protein C. Octanoyl-truncated ghrelin(1-15) activated GHSR1a-dependent signaling similar to the full-length peptide, as assayed using the cell-based early-growth factor 1 reporter system. Moreover, administration of the protein C-activating agent, ProTac, to mice enhanced the production of octanoyl ghrelin(1-15) in circulation. These results indicate that ghrelin is processed into shorter peptides in circulation under thrombotic and inflammatory conditions, although high doses of the short-form or full-length ghrelin did not have any obvious effects on thromboplastin time or platelet aggregation in human plasma. Truncation of ghrelin might be responsible for altering structural characteristics such as stability, hydrophobicity, and affinity with circulating macromolecules.
Asunto(s)
Endopeptidasas/metabolismo , Ghrelina/metabolismo , Plasma/enzimología , Proteína C/metabolismo , Animales , Proteínas Sanguíneas/aislamiento & purificación , Proteínas Sanguíneas/metabolismo , Bovinos , Endopeptidasas/sangre , Activación Enzimática , Ghrelina/sangre , Células HEK293 , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Células PC12 , RatasRESUMEN
OBJECTIVES: The serum alkaline phosphatase (ALP) level has shown to be a prognostic factor in myocardial infarction and peripheral vascular disease by its promoting effect on vascular calcification. A few recent studies also showed that elevated ALP levels were associated with mortality and unfavorable prognosis in coronary artery disease (CAD). Herein, we aimed to investigate the correlation between serum ALP levels and the severity of CAD by assessing the Gensini score. MATERIALS AND METHODS: A total of 470 patients with stable angina pectoris were evaluated retrospectively.Upon admission, their ALP levels were measured with an automated analyzer by the enzymatic method, and the severity of CAD was documented for each patient according to their Gensini score. Patients with a Gensini score greater than 40 were defined to have an advanced CAD. Serum ALP levels higher than 129 mg/dl in men and higher than 104 mg/dl in women were defined as the elevated ALP groups. RESULTS: The mean ALP level was 97.3±56.4, ranging from 15 to 485 U/l with 66.0/82.5/106.0 U/l percentile values, and elevated ALP levels were obtained in 79 cases (16.8%). In 70% of the patients (n=329), advanced CAD was diagnosed. The mean Gensini score was 85.6±29.4 in the advanced CAD group and 12.8±15.8 in the remainder of the patients. The advanced CAD group included more men, patients with diabetes mellitus, hypertension, and a reduced left ventricular ejection fraction, and patients with lower levels of high-density lipoprotein cholesterol and higher levels of creatinine, red cell distribution width, and mean platelet volume. ALP levels (105.4±60.7 vs. 78.4±38.7 U/l, P<0.001) and the frequency of patients with elevated ALP levels (22 vs. 5.0%, P<0.001) were significantly higher in the advanced CAD group. Regression analysis showed a significant correlation between increased levels of serum ALP and advanced CAD in univariate (odds ratio 1.015, 95% confidence interval 1.008-1.1291, P<0.001) and multivariate analyses (odds ratio 1.013, 95% confidence interval 1.003-1.023, P=0.01). CONCLUSION: Elevated ALP levels are associated with higher Gensini scores and a more severe form of CAD.
Asunto(s)
Angina Estable/enzimología , Proteínas Bacterianas/sangre , Enfermedad de la Arteria Coronaria/enzimología , Endopeptidasas/sangre , Adulto , Anciano , Anciano de 80 o más Años , Angina Estable/sangre , Angina Estable/diagnóstico por imagen , Biomarcadores/sangre , Distribución de Chi-Cuadrado , Angiografía Coronaria , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Oportunidad Relativa , Valor Predictivo de las Pruebas , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Regulación hacia Arriba , Adulto JovenRESUMEN
The renin-angiotensin system (RAS), vasopressin, and nitric oxide (NO) interact to regulate blood pressure at central and peripheral level. To improve our understanding of their interaction and their relationship with the hypothalamus and the cardiovascular system, we analyzed angiotensin- and vasopressin-metabolizing activities in hypothalamus (HT), left ventricle (LV), and plasma, collected from Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) treated or not with L-NAME [N(G)-nitro-L-arginine methyl ester], which inhibits the formation of NO and over-activates the sympathetic nervous system. Previous observations in WKY suggested higher formation of Ang III and Ang IV in the HT and higher availability of Ang II in plasma after L-NAME treatment. Our current results show higher formation of Ang IV and higher metabolism of vasopressin after treatment with L-NAME in the LV of WKY rats. In SHR treated with L-NAME, there is higher availability of Ang III in the HT leading to higher release of vasopressin together with lower formation of Ang 2-10. In their LV, however, there is an increase of vasopressinase. Interestingly, while the enzymatic activities in the HT and LV of WKY rats and control SHR are poorly correlated, they are well but inversely correlated in the L-NAME treated SHR. On the other hand, no significant correlations between enzymatic activities in HT or LV and plasma were noticed. Our results suggest that eNOS inhibition in SHR induces or enhances an inverse reciprocal interaction between HT and LV involving the RAS and vasopressin, which may be mediated by the autonomic nervous system.
Asunto(s)
Cistinil Aminopeptidasa/sangre , Endopeptidasas/sangre , Hipotálamo/enzimología , Miocardio/enzimología , NG-Nitroarginina Metil Éster/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Hipotálamo/efectos de los fármacos , Masculino , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY , Sistema Renina-Angiotensina/efectos de los fármacos , SolubilidadRESUMEN
PURPOSE: To investigate the relationship of the apoptosis regulators X-linked inhibitor of apoptosis (XIAP) and ubiquitin specific protease 8 (USP8) with clinical parameters, survival and response to chemotherapy in patients with advanced stages of non-small cell lung cancer (NSCLC). METHODS: The study included 34 NSCLC patients (28 females, 6 males) and 44 healthy individuals (17 males, 27 females) as a control group. XIAP and USP8 levels were determined by ELISA. RESULTS: The median serum XIAP level of the patients and the control group showed no significant difference. USP8 level was higher in patients than in controls (p<0.0001). In univariate analysis, there was no significant relationship between XIAP and USP8 serum levels and age, sex, performance status, weight loss, stage of disease, histopatological type and response to chemotherapy. Response to chemotherapy did not differ between the high and low XIAP and USP8 groups . There was no significant difference in progression- free survival (PFS) (p=0.432 and p=0.50, respectively) and overall survival (OS) (p=0.989 and p=0.90, respectively) between the low and high XIAP and USP8 groups. CONCLUSION: No relationship was found in serum XIAP and USP8 levels with clinical parameters, response to chemotherapy, PFS and OS in patients with advanced stages of NSCLC.
Asunto(s)
Biomarcadores de Tumor/sangre , Carcinoma de Pulmón de Células no Pequeñas/sangre , Endopeptidasas/sangre , Complejos de Clasificación Endosomal Requeridos para el Transporte/sangre , Neoplasias Pulmonares/sangre , Ubiquitina Tiolesterasa/sangre , Proteína Inhibidora de la Apoptosis Ligada a X/sangre , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/patología , Estudios de Casos y Controles , Distribución de Chi-Cuadrado , Supervivencia sin Enfermedad , Femenino , Humanos , Estimación de Kaplan-Meier , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estadificación de Neoplasias , Factores de Riesgo , Factores de Tiempo , Resultado del TratamientoRESUMEN
In cystic fibrosis (CF), if Pseudomonas aeruginosa (Pa) infection is not diagnosed and treated early, chronic colonization occurs, which causes rapid decline in pulmonary functions. The aim of this study was to evaluate Pa antibodies, compare them with Pa cultures and determine their role in early diagnosis and follow-up. Ninety CF patients were included; they were divided into chronic, intermittent, negative, and mucoid groups. They were evaluated every 3-6 months. In each visit, pulmonary function tests and sputum cultures were obtained, and Pa antibodies exotoxin A (ExoA), elastase (ELA) and alkaline protease (AP) were determined in the serum by enzyme-linked immunosorbent assay (ELISA). The most specific test that discriminated chronic colonized patients from noncolonized patients was Pa culture, and the presence of at least one antibody had the highest sensitivity. AP had the highest specificity, and ELA had the highest sensitivity. All antibodies were highest in the mucoid group. ELA was highest in chronic and lowest in the negative group. The presence of antibodies was much higher than positive Pa cultures in patients younger than five years of age. A negative correlation between forced expiratory volume in 1 second (FEV1) and AP was determined only in the mucoid group. In the two-year follow-up, antibody presence did not show a regular pattern. In CF, Pa antibodies can be early markers for diagnosis, especially in young children who cannot expectorate, but they should only be used together with sputum cultures for long-term follow-up and treatment.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Fibrosis Quística/diagnóstico , Pseudomonas aeruginosa/inmunología , ADP Ribosa Transferasas/sangre , Adolescente , Adulto , Proteínas Bacterianas/sangre , Toxinas Bacterianas/sangre , Niño , Preescolar , Continuidad de la Atención al Paciente , Endopeptidasas/sangre , Ensayo de Inmunoadsorción Enzimática , Exotoxinas/sangre , Femenino , Humanos , Lactante , Masculino , Elastasa Pancreática/sangre , Pruebas de Función Respiratoria , Factores de Virulencia/sangre , Adulto Joven , Exotoxina A de Pseudomonas aeruginosaRESUMEN
This study was aimed to set up and evaluate a quantitative method for detecting lumbrokinase level in plasma. The lumbrokinase was used to immunize rabbit and BALB/c mouse for preparation of rabbit or mouse-derived polyclonal antibodies, and then the standard curves were drawn up by detecting the lumbrokinase diluted in PBS using the double antibody sandwich ELISA. This method further was analyzed for its specificity, precision and recovery rate. This established double antibody sandwich ELISA was used to assay the lumbrokinase in human plasma, and the assayed results were assessed. The results showed that a double antibody sandwich ELISA for the detection of lumbrokinase has been established. And the standard curve fitting R value > 0.99, the precision assessment showed that the measured values of coefficient of variation (CV) in 3 batches were all < 15%; recovery assessment in 3 batches showed that all the measured recovery rates were > 80%; the quantitative low limit was assessed as 5 ng/ml (precision CV < 15%, recovery rate > 85%). It is concluded that this method is consistent with the criteria stipulated by the Pharmacopeia, which provides a reliable measurement method for quantitative detection of plasma lumbrokinase in clinical trials.
Asunto(s)
Endopeptidasas/sangre , Ensayo de Inmunoadsorción Enzimática/métodos , Animales , Humanos , Ratones , Ratones Endogámicos BALB C , Plasma , ConejosRESUMEN
There is a reciprocal connection between the frontal cortex (FC) and cardiovascular function, and this connection is functionally lateralized. The possible pathophysiological impact of neuroendocrine asymmetries is largely underestimated. Our aim was to examine the activity of soluble (SOL) and membrane-bound (MB) aminopeptidases (APs) involved in the renin-angiotensin system in the peripheral plasma and in the left and right FC, in both untreated (control) and captopril-treated spontaneously hypertensive rats (SHRs). Enzymatic activities were measured fluorometrically using arylamide derivatives as substrates. Captopril reduced systolic blood pressure, but no differences in plasma AP activity were observed between the control and treated SHRs. In contrast, whereas the bilateral pattern (left vs. right differences) of SOL activities did not substantially change in the FC after captopril treatment, the asymmetries observed for MB activities in the FC markedly increased compared with the control group. Moreover, correlations between the AP activities in the plasma and those in the left or right FC were observed. In the control rats, the plasma AP activities correlated significantly with those in the right FC, whereas they correlated with those in the left FC in the captopril-treated group. In both groups (control and captopril), these correlations were negative for the SOL activity but positive for the MB activity. The present results reveal a pattern of bilateral behavior between the nervous and cardiovascular systems. The inverted bilateral behavior after captopril treatment suggests a systematized, lateralized neuroendocrine response representing a regular bilateral behavior that has yet to be analyzed.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Presión Sanguínea/efectos de los fármacos , Captopril/farmacología , Endopeptidasas/efectos de los fármacos , Endopeptidasas/metabolismo , Lóbulo Frontal/metabolismo , Sistema Renina-Angiotensina/efectos de los fármacos , Aminopeptidasas/metabolismo , Animales , Estudios de Casos y Controles , Endopeptidasas/sangre , Lóbulo Frontal/efectos de los fármacos , Lateralidad Funcional/efectos de los fármacos , Ratas , Ratas Endogámicas SHRRESUMEN
PURPOSE: The aim of this study was to investigate the putative changes in serum angiotensinase activities (aminopeptidase N, APN; aminopeptidase B, APB; aminopeptidase A, APA; aspartyl aminopeptidase, ASAP) involved in the renin-angiotensin system (RAS) in women with breast cancer treated or not with a neoadjuvant therapy of paclitaxel and anthracycline and in healthy women volunteers. METHODS: We fluorometrically analysed serum APN, APB, APA and ASAP activities using their corresponding aminoacyl-ß-naphthylamides as substrates in women with breast cancer treated with a neoadjuvant therapy of paclitaxel and anthracycline. RESULTS: When compared with healthy controls, women with breast cancer not treated with neoadjuvant chemotherapy, showed a decrease in angiotensinase activity, which support the putative increase of angiotensin II (Ang II) levels, indicating that the tumour process would favour the development of the disease. Also, an increase in APN and APB activities was observed, which support a role for angiotensin IV (Ang IV). In women treated with a neoadjuvant therapy, we described an increase in ASAP and APA activities, supporting the idea that this treatment increases Ang II catabolism. The resulting decrease in Ang II level could lead to an inhibition of the tumour growth. CONCLUSION: Present results show changes in serum angiotensinase activities in women with breast cancer and in women with breast cancer treated with a neoadjuvant therapy of paclitaxel and anthracycline. Therefore, considerable attention should be focused on the development of RAS blockade therapy as a new strategy for breast cancer treatment.
Asunto(s)
Aminopeptidasas/sangre , Antraciclinas/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Endopeptidasas/sangre , Terapia Neoadyuvante/métodos , Paclitaxel/uso terapéutico , Sistema Renina-Angiotensina/efectos de los fármacos , Angiotensina II/análogos & derivados , Angiotensina II/sangre , Antraciclinas/farmacología , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/sangre , Femenino , Glutamil Aminopeptidasa/sangre , Humanos , Persona de Mediana Edad , Naftalenos/sangre , Paclitaxel/farmacología , Valores de ReferenciaRESUMEN
OBJECTIVES: To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to anti-dsDNA antibody levels. METHODS: Sixty-one patients with refractory SLE were treated with a standard rituximab regimen. Clinical and serological measures of disease activity and B-cell numbers were assessed. B-cell phenotype was examined in a subgroup of patients by flow cytometry. RESULTS: Disease relapse was substantially delayed beyond B-cell repopulation, and early relapse was associated with a faster rate of repopulation. At relapse, B-cell numbers were significantly lower than at baseline in patients with high anti-dsDNA antibody levels (> 100 IU/ml) but not in patients with low anti-dsDNA antibody levels. Of the patients with high anti-dsDNA antibodies at baseline, levels fell significantly only in those patients who remained in remission after repopulation. Relapse with high anti-dsDNA antibody levels was associated with an increased percentage of IgD(-)CD27(hi) plasmablasts, whereas relapse with low anti-dsDNA antibody levels was accompanied by an increased percentage of IgD(-)CD27(-) B cells. CONCLUSION: Anti-dsDNA antibody levels distinguished two patient groups, which differ in their B-cell number and phenotype at relapse following rituximab, and suggest that different B-cell pathologies exist in SLE. The data imply that B-cell numbers should be kept very low for a sustained period in patients with high dsDNA binding, therefore justifying a more aggressive regimen.
Asunto(s)
Anticuerpos Antinucleares/sangre , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Linfocitos B/patología , Endopeptidasas/inmunología , Inmunidad Celular , Lupus Eritematoso Sistémico/inmunología , Adolescente , Adulto , Anciano , Anticuerpos Antinucleares/inmunología , Antígenos CD20 , Linfocitos B/inmunología , Linfocitos B/metabolismo , Niño , Endopeptidasas/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Humanos , Factores Inmunológicos/uso terapéutico , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/patología , Masculino , Persona de Mediana Edad , Fenotipo , Rituximab , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVES: Proteolytic degradation of aggrecan is a hallmark of the pathology of osteoarthritis. The aim of this study was to develop enzyme-linked immunosorbent assay (ELISA) to quantify the serum levels of specific aggrecan fragments generated by aggrecanases-mediated cleavage. We investigated the relationships between these two aggrecan degradations fragments and urinary CTX-II levels. METHODS: The competitive ELISAs employ a polyclonal antibody raised against the aggrecan fragments containing two neoepitopes NITEGE(373)and (374)ARGSVI. We measured serum levels of ARGSV and NITEGE in 125 women with knee osteoarthritis (mean±SD age of 53.6±7.6 years, mean±SD disease duration of 3.6±3.8 years), and 57 women age-matched controls. RESULTS: Aggrecan neoepitopes assays showed an intra- and inter-assay imprecision (CV) lower than 20% for both tests and good linearity. Median serum ARGSVI (by 18%; P=0.002), and NITEGE (36.4%; P<0.001) levels were significantly decreased in patients with knee osteoarthritis compared with controls. Minimal joint space width was negatively correlated with ARGSVI (r=-0.368, P=0.04) and NITEGE (r=-0.274, P=0.038) in knee osteoarthritis patients. Median urinary CTX-II levels were significantly increased by 39.5% (P=0.001) in knee OA patients compared with controls. CONCLUSION: Markers of degradation aggrecan were analyzed for the first time in an African osteoarthritis population. These markers can be used to monitor aggrecanase activity in human joint disease. Their combination with CTX-II can improve clinical investigation of patients with osteoarthritis patients.